Show Summary Details
Page of

Mesangiocapillary glomerulonephritis 

Mesangiocapillary glomerulonephritis
Mesangiocapillary glomerulonephritis

Peter W. Mathieson



Novel therapies aimed at complement inhibition, e.g. eculizumab, offer exciting potential in this group of diseases, but clinical experience is very limited.

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 27 September 2021

Mesangiocapillary glomerulonephritis (MCGN)—which is synonymous with membranoproliferative glomerulonephritis—is diagnosed when renal biopsy reveals glomeruli with a characteristic lobular appearance. Immunohistology and electron microscopy allow further subdivision into three patterns, types I, II (also called dense deposit disease), and III. Clinical presentation is with proteinuria (sometimes nephrotic syndrome) and/or haematuria; hypertension and/or impairment of excretory kidney function may be associated....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.